How Wegovy is made: the science behind semaglutide

Step 1 (Producing the semaglutide peptide through fermentation

The starting point for Wegovy's active ingredient is a short protein chain of 31 amino acids, based on the structure of human GLP-1 (glucagon-like peptide-1)) a hormone the gut releases after a meal to signal fullness and regulate blood glucose. Novo Nordisk engineers Saccharomyces cerevisiae yeast cells to carry the genetic instructions for producing this peptide. The modified yeast is grown in large fermentation tanks; as it multiplies, it expresses the semaglutide precursor protein into the culture medium.

Once fermentation reaches the right yield, the culture is harvested. The raw protein is separated from the yeast cells and growth medium through a series of filtration steps, then refined further using chromatography columns that select for the correct molecular structure and remove impurities. This stage is not unlike the process used to make insulin (also produced in yeast or bacteria) and you can read more about how semaglutide's synthesis compares to similar medicines on our semaglutide manufacturing overview.

Quality is monitored at every point: batch samples are tested for identity, purity, and potency against defined specifications before the process moves forward. A batch that does not meet those specifications is discarded, not released.

Step 2, Chemical modification to make the weekly dose possible

The peptide produced in fermentation would be broken down by the body within minutes if injected unmodified. Two deliberate changes give semaglutide its characteristic week-long action.

First, two amino acid substitutions are made at specific positions in the chain, making the molecule resistant to the enzyme (DPP-4) that would otherwise degrade natural GLP-1 very rapidly. Second, and more significant for dosing convenience, a long fatty-acid chain is attached via a linker molecule. This side chain binds non-covalently to albumin (a protein that circulates continuously in the blood) creating a reversible depot that releases semaglutide slowly and keeps plasma concentrations stable between weekly injections.

The same fatty-acid conjugation strategy is what distinguishes semaglutide from earlier GLP-1 medicines. It is not a simple tweak; it required years of medicinal chemistry work and is part of what makes Wegovy as a finished product structurally distinct from liraglutide and other predecessors. The NHS semaglutide medicines page describes how the medicine works at a patient level if you want a less technical summary.

Step 3 (Formulation, filling, and the finished pen

The modified semaglutide is dissolved in a buffered aqueous solution alongside excipients) inactive ingredients that stabilise the active molecule, adjust pH, and prevent microbial growth during the pen's shelf life. The specific excipients used are listed in the Wegovy Summary of Product Characteristics (SmPC), published on the eMC, which is the authoritative reference for pharmaceutical composition.

The solution is filled into cartridges under aseptic conditions, meaning in environments kept free of microorganisms through filtered air, strict gowning, and continuous environmental monitoring. The cartridges are then assembled into the pre-set injection pens at the doses used in the titration schedule (0.25 mg through to 2.4 mg, and now 7.2 mg following the MHRA's approval of the higher-dose pen in April 2026).

Novo Nordisk manufactures Wegovy at facilities audited against Good Manufacturing Practice (GMP) standards. More detail on where production sites are located is covered in our companion page on where Wegovy is made, and background on the company behind the medicine is on our Wegovy manufacturer page.

Each finished batch undergoes release testing (checking sterility, potency, and particulate content) before any pens leave the facility. That testing requirement applies regardless of which market the batch is destined for.

What this means if you are considering Wegovy for weight management

Understanding what Wegovy is made of and how it reaches the finished pen matters practically. The biological complexity of the manufacturing process is one reason counterfeit versions of weight-loss injections are genuinely dangerous: replicating pharmaceutical-grade semaglutide outside a licensed facility is not feasible, which means fake pens contain something else entirely. The MHRA has warned publicly about counterfeit pens sold through social media and unverified online sellers, and has conducted major seizures of illegally traded weight-loss medicines. Sourcing through a GPhC-registered pharmacy, with supply from the licensed UK chain, is the safest route.

For context on what private treatment costs and what is included in that price, our Wegovy pricing page sets out the market picture honestly. If you are weighing up whether an oral alternative might suit you better, Wegovy is now also available as a once-daily tablet, the manufacturing approach for that formulation is quite different, centred on an absorption-enhancing co-formulation rather than injection, and is covered on our Wegovy tablet page.

A prescriber at nume (sorry, at nume) reviews every consultation the same day it is submitted, drawing on your full health picture before any prescription is issued. If you would like to find out whether Wegovy is clinically suitable for you, check your eligibility with a free consultation.